Bullfrog AI (BFRG) Competitors $2.09 -0.02 (-0.95%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BFRG vs. KPTI, QNCX, PMVP, ALXO, GNLX, ENTX, CLSD, ELYM, IKNA, and IMABShould you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Karyopharm Therapeutics (KPTI), Quince Therapeutics (QNCX), PMV Pharmaceuticals (PMVP), ALX Oncology (ALXO), Genelux (GNLX), Entera Bio (ENTX), Clearside Biomedical (CLSD), Eliem Therapeutics (ELYM), Ikena Oncology (IKNA), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Bullfrog AI vs. Karyopharm Therapeutics Quince Therapeutics PMV Pharmaceuticals ALX Oncology Genelux Entera Bio Clearside Biomedical Eliem Therapeutics Ikena Oncology I-Mab Bullfrog AI (NASDAQ:BFRG) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Do institutionals & insiders have more ownership in BFRG or KPTI? 1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 33.9% of Bullfrog AI shares are held by company insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, BFRG or KPTI? Bullfrog AI has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Does the media refer more to BFRG or KPTI? In the previous week, Bullfrog AI had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Bullfrog AI and 0 mentions for Karyopharm Therapeutics. Bullfrog AI's average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score. Company Overall Sentiment Bullfrog AI Neutral Karyopharm Therapeutics Neutral Does the MarketBeat Community prefer BFRG or KPTI? Karyopharm Therapeutics received 535 more outperform votes than Bullfrog AI when rated by MarketBeat users. CompanyUnderperformOutperformBullfrog AIN/AN/AKaryopharm TherapeuticsOutperform Votes53572.20% Underperform Votes20627.80% Which has stronger valuation & earnings, BFRG or KPTI? Bullfrog AI has higher earnings, but lower revenue than Karyopharm Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K303.50-$5.36M-$0.85-2.46Karyopharm Therapeutics$148.44M0.54-$143.10M-$1.14-0.56 Is BFRG or KPTI more profitable? Bullfrog AI has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -58.93%. Karyopharm Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -141.39% -124.63% Karyopharm Therapeutics -58.93%N/A -41.25% Do analysts rate BFRG or KPTI? Karyopharm Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 687.40%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKaryopharm Therapeutics beats Bullfrog AI on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Bullfrog AI News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRG vs. The Competition Export to ExcelMetricBullfrog AIPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.21M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-2.4610.5589.7417.16Price / Sales303.50196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book4.865.094.784.78Net Income-$5.36M$151.83M$120.31M$225.60M7 Day Performance-5.86%-2.14%-1.92%-1.23%1 Month Performance6.09%-4.56%13.65%0.46%1 Year Performance-23.72%8.87%28.34%15.24% Bullfrog AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRGBullfrog AI0.7327 of 5 stars$2.09-0.9%N/A-24.8%$18.21M$60,000.00-2.464News CoverageKPTIKaryopharm Therapeutics3.8015 of 5 stars$0.67-4.6%$5.00+648.5%-16.5%$84.30M$148.44M-0.61380QNCXQuince Therapeutics2.8951 of 5 stars$1.89-6.9%$8.50+349.7%+63.3%$83.16MN/A-1.6460Analyst ForecastAnalyst RevisionNews CoveragePMVPPMV Pharmaceuticals1.7863 of 5 stars$1.58flat$5.80+267.1%-45.8%$81.77MN/A0.0050Positive NewsALXOALX Oncology3.1952 of 5 stars$1.55+6.9%$10.67+588.2%-87.6%$81.75MN/A-0.5440Analyst ForecastNews CoverageGNLXGenelux0.8843 of 5 stars$2.33flat$18.25+683.3%-83.8%$80.47M$8,000.00-2.4510ENTXEntera Bio1.4242 of 5 stars$2.18+0.9%$10.00+358.7%+208.8%$78M$130,000.00-8.5020CLSDClearside Biomedical2.8771 of 5 stars$1.03+0.5%$5.33+420.3%-16.1%$77.74M$8.23M-2.2930News CoverageELYMEliem TherapeuticsN/A$2.60-7.8%N/A-24.4%$77.36MN/A-4.9120IKNAIkena Oncology2.8725 of 5 stars$1.60-3.0%$3.00+87.5%-22.5%$77.21M$659,000.00-1.3470IMABI-Mab2.5162 of 5 stars$0.95-5.4%$8.00+745.8%-40.8%$77.08M$3.27M0.0034Gap Down Related Companies and Tools Related Companies Karyopharm Therapeutics Competitors Quince Therapeutics Competitors PMV Pharmaceuticals Competitors ALX Oncology Competitors Genelux Competitors Entera Bio Competitors Clearside Biomedical Competitors Eliem Therapeutics Competitors Ikena Oncology Competitors I-Mab Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BFRG) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bullfrog AI Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bullfrog AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
